PMC9891450_01
Trends in IgM (A) and B lymphocytes (B) over the period from the infusion of anti-CD19 CAR-T cell therapy to the time of post-infusion ABO blood group antibody potency measurement. CAR-T = chimeric antigen receptor T cell.
bs9-5-62-g001.jpg
PMC9891450_01_bs9-5-62-g001.jpg
F1
IgM and B-cell percentage. In our study, all 9 patients showed a decreasing trend, except for patient no. 6 who showed a decrease and then an increase in IgM (Fig. 1A). Meanwhile, all 9 patients showed a decreasing B lymphocyte percentage, except for patient no. 6 who showed a decreasing and then increasing B lymphocyte percentage (Fig. 1B).
Therapies (reinfusion CAR-T for "*" and HSCT for green and white intermixed colors) and clinical outcomes (complete remission and complete remission with incomplete hematological recovery for green; relapse for orange and death for red) are represented concerning time in months. CAR-T = chimeric antigen receptor T cell. HSCT = hematopoietic stem cell transplantation.
bs9-5-62-g002.jpg
PMC9891450_01_bs9-5-62-g002.jpg
F2
However, in patients receiving CD19 CAR-T cells immunotherapy, there was no significant causal relationship between serum ABO blood group antibody potency and their clinical outcome Table 1 and Fig. 2.